Skip to main content Skip to section navigation Skip to footer
Maravai LifeSciences
  • Contact
  • About
    • About Maravai
    • Leadership
    • Board of Directors
    • Innovation
    • Supply Chain
    • Operations
    • Diversity, Equity, and Inclusion
  • Brands
    • Our Brands
    • TriLink BioTechnologies
    • Cygnus Technologies
    • Glen Research
    • Alphazyme
  • Impact
    • Our Impact
    • Maravai Foundation
  • Insights
    • Our Insights
    • Maravai Insights
    • From the Science and Innovation Office
    • Latest news
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • ESG
    • Governance
  • Careers
    • Be a #MiracleMaker
    • Current Openings
    • Benefits and Growth
    • Culture and People

Press releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
    • R&D Day 2023
  • Company Info
    • Company Profile
    • Leadership
    • Annual Reports & Proxy
    • Contacts
    • FAQ
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • ESG
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Policy
  • News & Events

  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
  • R&D Day 2023
May 1, 2025 7:30 AM EDT

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025

Mar 18, 2025 4:05 PM EDT

Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025 6:00 AM EST

Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

Feb 3, 2025 6:00 AM EST

TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe

Jan 28, 2025 4:01 PM EST

Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies

Jan 8, 2025 4:10 PM EST

Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

Dec 5, 2024 4:05 PM EST

Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Nov 12, 2024 8:05 AM EST

Maravai LifeSciences Announces November 2024 Investor Conference Schedule

Nov 7, 2024 4:01 PM EST

Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research

Nov 7, 2024 4:01 PM EST

Maravai LifeSciences Reports Third Quarter 2024 Financial Results

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 11
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Maravai LifeSciences and its brands are the proven catalysts for helping deliver novel vaccines, therapeutics and diagnostics with biotech, biopharma and life sciences companies across the globe.

Extraordinary science.
Everyday miracles.

  • About
    • Leadership
    • Board of Directors
    • Innovation
    • Supply chain
    • Operations
    • Diversity, equity, and inclusion
  • Brands
    • TriLink BioTechnologies
    • Cygnus Technologies
    • Glen Research
    • Alphazyme
  • Helpful links
    • Investors
    • Insights
    • Be a #MiracleMaker
    • Current openings

Share price

Connect with us

  • LinkedIn
  • Terms
  • Privacy notice
  • Site map
© 2025 Maravai LifeSciences. All rights reserved

Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.